Skip to content

    Lung Cancer Health Center

    Font Size
    A
    A
    A

    Drugs That Control Genes May Treat Lung Cancer

    Researchers Report Some Success Against Advanced Lung Cancer With Epigenetic Drugs
    By
    WebMD Health News
    Reviewed by Laura J. Martin, MD

    Nov. 9, 2011­ -- A new approach to treating cancer appears to help certain patients with advanced lung cancer, and researchers say they think they may have a way of spotting those who will benefit.

    The small study is generating big excitement in the world of cancer treatment because it demonstrates that so-called epigenetic drugs may work when traditional chemotherapy has failed.

    Epigenetic drugs work by controlling gene expression -- the way information from genes is used to create products such as proteins.

    The study is published in Cancer Discovery.

    "This is a ... groundbreaking study, showing that by modifying the epigenetics of a cancer cell we can get real responses in lung cancer," said Jeffrey A. Engleman, MD, PhD, director of thoracic oncology at Massachusetts General Hospital, in Boston, in a news briefing. "And getting real responses in lung cancer is actually quite difficult, so we take special notice of therapies that can do this." He was not involved in the research.

    New Approach to Treating Cancer

    All 45 patients recruited for the study had non-small-cell lung cancer, the leading cancer killer in the U.S.

    All had tumors that had spread beyond their lungs despite treatment with an average of three other therapies.

    "These are patients with very advanced disease" who have little chance of survival, says study researcher Charles Rudin, MD, PhD. He is professor of oncology and associate director for clinical research at Johns Hopkins University Kimmel Cancer Center in Baltimore.

    Rudin says that he has consulted for Syndax Pharmaceuticals, the company that makes one of the drugs tested in the study.

    Most patients with cancer this advanced are only expected to survive for about four months, the researchers note.

    After treatment with a combination of the medications Vidaza, which is FDA approved to treat certain rare blood disorders, and the experimental pill entinostat, however, the average survival for the entire group was 6.4 months.

    Doctors who wrote an editorial on the study note that this result was just shy of the same average survival (6.7 months) seen in patients treated with Tarceva, the only medication that's approved to treat patients with non-small-cell lung cancer that has spread to other organs.

    1 | 2 | 3

    Today on WebMD

    Xray analysis
    Do you know the myths from the facts?
    chest x-ray
    Get to know them.
     
    woman taking pills
    Tips to managing them.
    Lung cancer xray
    See it in pictures, plus read the facts.
     
    Lung Cancer Risks Myths and Facts
    SLIDESHOW
    Woman getting ct scan
    Article
     
    Improving Lung Cancer Survival Targeted Therapy
    VIDEO
    cancer fighting foods
    Article
     
    Lung Cancer Surprising Differences Between Sexes
    VIDEO
    Pets Improve Your Health
    SLIDESHOW
     
    Vitamin D
    SLIDESHOW
    Lung Cancer Surgery Options
    VIDEO